FEDERAL DEMONSTRATION PARTNERSHIP
Redefining the Government & University Research Partnership

Subrecipient Statement of Intent

PASS-THROUGH ENTITY (PTE) INSTITUTION INFORMATION	
PTE PI	
PTE Institution	
Prime Sponsor	
Project Title	

SUBRECIPIENT INSTITUTION INFORMATION					
Institution	Loyola University of Chicago				
UEI	RFRPFMNR8LA5	EIN	1361408475A2		
PI Name		eRA Commons			
PI Phone		PI E-Mail			
Project Period					
Performance Site Address	2160 S. 1st Ave, Maywood, IL 60153	Performance Site Congressional District #	IL-007		
Direct Costs		F&A Costs		Total Costs	
SUBRECIPIENT CONTACTS					
Administrative		E-Mail			
[redacted]	[redacted]	Phone			
Authorized Official	Meharvan Singh, PhD; Vice Provost for Research	E-Mail	researchhsd@luc.edu		
[redacted]	[redacted]	Phone	464-220-9660		

	YES/NO	APPROVAL DATE OR PENDING		YES/NO	APPROVAL DATE OR PENDING
Human Subjects	Select...		Recombinant DNA	Select...	
Vertebrate Animals	Select...		Program Income	Select...	[redacted]
Human Embryonic Stem Cells	Select...		Cost Sharing	Select...	
Select Agents	Select...				

In signing below and offering to participate in this research program, the Subrecipient Institution certifies that neither they nor their principals are presently debarred, suspended, proposed for debarment, declared ineligible or voluntarily excluded from receiving funds from any federal department or agency and are not delinquent on any federal debt; they are in compliance with the Drug Free Workplace Act of 1988; they are in compliance with U.S. Code, Section 1352, restrictions on the use of federal funds for the purpose of lobbying; they have filed annually with the Office of Scientific Integrity governing Misconduct in Science; they have filed with DHHS compliance offices certification forms governing Civil Rights (441), Handicapped Individuals (641), Sex Discrimination (639-A), and Age Discrimination (680); they are in compliance with PHS policy governing Program Income; they have established policies in compliance with 45 CFR Part 46, Subpart A (protection of human subjects); the Animal Welfare Act (PL-89-544 as amended) and the Health Research Exchange Act of 1985 (Public Law 99-158); and that they are in compliance with NIH guidelines regarding human pluripotent stem cell research, transplantation of fetal tissue, recombinant DNA and human gene transfer research, and inclusion of women, children & minorities in research. This proposal has been reviewed and approved by the appropriate official(s) of Subrecipient and certified to its accuracy and completeness. At the time of submission, the appropriate programmatic and administrative personnel of Subrecipient involved in this application are aware of the prime awarding agency's policies and other regulatory requirements applicable to institutions and investigators, agree to accept the obligation to comply with award terms, conditions, certifications, and required trainings, and are prepared to establish the necessary inter-institutional agreement consistent with that policy. Any terms or rates included in the proposal described herein are not binding upon the Pass-Though Entity. All terms and conditions between the parties will be outlined in a separate formal Agreement. I certify to the best of my knowledge and belief that the information provided herein is true, complete, and accurate. I am aware that the provision of false, fictitious, or fraudulent information, or the omission of any material fact, may subject me to criminal, civil, or administrative consequences including, but not limited to violations of U.S. Code Title 18, Sections 2, 1001, 1343 and Title 31, Sections 3729-3730 and 3801-3812.

SUBRECIPIENT INSTITUTIONAL OFFICIAL:

Meharvan Singh, PhD; Vice Provost for Research

Name and Title

Signature and Date